The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients-Reference-Cited by-同舟云学术

The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients

Published:2022-12-09 Issue:7 Volume:12 Page:7699-7712
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Willemsen Anna C. H.¹²³^ORCID,De Moor Nina⁴^ORCID,Van Dessel Jeroen⁵^ORCID,Baijens Laura W. J.²⁶^ORCID,Bila Michel⁵^ORCID,Hauben Esther⁷^ORCID,van den Hout Mari F. C. M.²⁸^ORCID,Vander Poorten Vincent⁴⁹^ORCID,Hoeben Ann¹²^ORCID,Clement Paul M.⁴^ORCID,Schols Annemie M. W. J.³^ORCID

Affiliation:

1. Division of Medical Oncology, Department of Internal Medicine Maastricht University Medical Center+ Maastricht The Netherlands

2. GROW‐School of Oncology and Developmental Biology Maastricht University Medical Center+ Maastricht The Netherlands

3. Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism Maastricht University Medical Center+ Maastricht The Netherlands

4. Department of Oncology Leuven Cancer Institute, KU Leuven Leuven Belgium

5. Department of Biomedical Sciences, KU Leuven & Oral and Maxillofacial Surgery University Hospitals Leuven Leuven Belgium

6. Department of Otorhinolaryngology, Head and Neck Surgery Maastricht University Medical Center+ Maastricht The Netherlands

7. Department of Pathology University Hospitals Leuven Leuven Belgium

8. Department of Pathology Maastricht University Medical Center+ Maastricht The Netherlands

9. Otorhinolaryngology Head and Neck Surgery University Hospitals Leuven, Leuven Cancer Institute, KU Leuven Leuven Belgium

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5522

Reference43 articles.

1. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

2. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

3. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

4. Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer

5. Immune landscape of viral‐ and carcinogen‐driven head and neck cancer;Cillo AR;Immunity,2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory markers as prognostic markers in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis;Frontiers in Oncology;2024-07-26

2. The Prognostic Correlation of Heart rate variability and body weight status in liver cancer patients;2024-06-18

3. Influence of cachexia on immunotherapy efficacy and prognosis for malignant tumors of the digestive system;Cancer Reports;2024-05

4. Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients;Aging;2024-03-11

5. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors;Journal of Cancer Research and Clinical Oncology;2023-12